158 related articles for article (PubMed ID: 31842643)
21. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
[TBL] [Abstract][Full Text] [Related]
22. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Flinn IW; Gribben JG; Dyer MJS; Wierda W; Maris MB; Furman RR; Hillmen P; Rogers KA; Iyer SP; Quillet-Mary A; Ysebaert L; Walter HS; Verdugo M; Klein C; Huang H; Jiang Y; Lozanski G; Pignataro DS; Humphrey K; Mobasher M; Kipps TJ
Blood; 2019 Jun; 133(26):2765-2775. PubMed ID: 30862645
[TBL] [Abstract][Full Text] [Related]
23. Obinutuzumab: the more the merrier?
Burger JA
Blood; 2016 Jan; 127(1):6-8. PubMed ID: 26744434
[TBL] [Abstract][Full Text] [Related]
24. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.
Leblond V; Aktan M; Ferra Coll CM; Dartigeas C; Kisro J; Montillo M; Raposo J; Merot JL; Robson S; Gresko E; Bosch F; Stilgenbauer S; Foà R
Haematologica; 2018 Nov; 103(11):1889-1898. PubMed ID: 29976743
[TBL] [Abstract][Full Text] [Related]
25. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
26. Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.
Tam C; Kuss B; Opat S; Boulos J; Marlton P
Intern Med J; 2017 Jul; 47 Suppl 4():5-10. PubMed ID: 28685928
[TBL] [Abstract][Full Text] [Related]
27. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.
Cartron G; de Guibert S; Dilhuydy MS; Morschhauser F; Leblond V; Dupuis J; Mahe B; Bouabdallah R; Lei G; Wenger M; Wassner-Fritsch E; Hallek M
Blood; 2014 Oct; 124(14):2196-202. PubMed ID: 25143487
[TBL] [Abstract][Full Text] [Related]
28. Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation.
Kakkar AK; Balakrishnan S
J Oncol Pharm Pract; 2015 Oct; 21(5):358-63. PubMed ID: 24827578
[TBL] [Abstract][Full Text] [Related]
29. Clinical application of obinutuzumab for treating chronic lymphocytic leukemia.
Luan C; Chen B
Drug Des Devel Ther; 2019; 13():2899-2909. PubMed ID: 31692500
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Al-Sawaf O; Zhang C; Tandon M; Sinha A; Fink AM; Robrecht S; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Tausch E; Schary W; Ritgen M; Wendtner CM; Kreuzer KA; Eichhorst B; Stilgenbauer S; Hallek M; Fischer K
Lancet Oncol; 2020 Sep; 21(9):1188-1200. PubMed ID: 32888452
[TBL] [Abstract][Full Text] [Related]
31. Update on obinutuzumab in the treatment of B-cell malignancies.
Illidge T; Cheadle EJ; Donaghy C; Honeychurch J
Expert Opin Biol Ther; 2014 Oct; 14(10):1507-17. PubMed ID: 25190612
[TBL] [Abstract][Full Text] [Related]
32. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Michallet AS; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; de Guibert S; Orsini F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Lévy V; Nguyen-Khac F; Le Garff-Tavernier M; Aanei C; Ticchioni M; Letestu R; Feugier P
Lancet Haematol; 2019 Sep; 6(9):e470-e479. PubMed ID: 31324600
[TBL] [Abstract][Full Text] [Related]
33. Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report.
Lachowiez C; Deodhar A; Kozin E; Spurgeon S
Am J Case Rep; 2017 May; 18():516-519. PubMed ID: 28487504
[TBL] [Abstract][Full Text] [Related]
34. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M
N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681
[TBL] [Abstract][Full Text] [Related]
35. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
36. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
Karlsson C; Hansson L; Celsing F; Lundin J
Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
[TBL] [Abstract][Full Text] [Related]
37. Obinutuzumab for B-cell malignancies.
Owen CJ; Stewart DA
Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
[TBL] [Abstract][Full Text] [Related]
38. U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
Lee HZ; Miller BW; Kwitkowski VE; Ricci S; DelValle P; Saber H; Grillo J; Bullock J; Florian J; Mehrotra N; Ko CW; Nie L; Shapiro M; Tolnay M; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
Clin Cancer Res; 2014 Aug; 20(15):3902-7. PubMed ID: 24824310
[TBL] [Abstract][Full Text] [Related]
39. Obinutuzumab in hematologic malignancies: lessons learned to date.
Illidge T; Klein C; Sehn LH; Davies A; Salles G; Cartron G
Cancer Treat Rev; 2015 Nov; 41(9):784-92. PubMed ID: 26190254
[TBL] [Abstract][Full Text] [Related]
40. [Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia].
Šimkovič M; Vodárek P; Motyčková M; Žák P; Smolej L
Vnitr Lek; 2015; 61(7-8):626-32. PubMed ID: 26375688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
